INTRODUCTION: Treatment of intermittent claudication (IC) due to peripheral arterial disease (PAD) is aimed at improving walking distance and includes secondary prevention of cardiovascular disease. Both supervised exercise therapy (SET) and percutaneous transluminal angioplasty (PTA) have proven to be effective in increasing maximum and pain-free walking distance in IC. However, the optimal treatment strategy in patients with IC due to iliac artery stenosis or occlusion remains unclear. OBJECTIVE: To compare the (cost-) effectiveness of initial PTA versus initial SET in patients with disabling IC due to an iliac artery obstruction. DESIGN: In a multicentre randomised controlled trial 400 consecutive patients with IC will be randomly assigned to PTA (with additional stent placement on indication) or SET. Primary outcomes are maximum walking distance and health-related quality of life measured using the disease-specific VascuQol instrument after 1 year. Secondary outcomes are pain-free walking distance, functional status, generic quality of life, complications related to each of the interventions, additional interventions, treatment failures and costs (cost-effectiveness and cost-utility) after 1 year. CONCLUSION AND IMPLICATIONS: Based on the results of this proposed large study well-founded adjustments of existing guidelines on the treatment of iliac artery occlusive disease can be implemented (Clinical Trials.gov NCT01385774; Nederlands Trial Register NTR2776). Copyright Â
RCT Entities:
INTRODUCTION: Treatment of intermittent claudication (IC) due to peripheral arterial disease (PAD) is aimed at improving walking distance and includes secondary prevention of cardiovascular disease. Both supervised exercise therapy (SET) and percutaneous transluminal angioplasty (PTA) have proven to be effective in increasing maximum and pain-free walking distance in IC. However, the optimal treatment strategy in patients with IC due to iliac artery stenosis or occlusion remains unclear. OBJECTIVE: To compare the (cost-) effectiveness of initial PTA versus initial SET in patients with disabling IC due to an iliac artery obstruction. DESIGN: In a multicentre randomised controlled trial 400 consecutive patients with IC will be randomly assigned to PTA (with additional stent placement on indication) or SET. Primary outcomes are maximum walking distance and health-related quality of life measured using the disease-specific VascuQol instrument after 1 year. Secondary outcomes are pain-free walking distance, functional status, generic quality of life, complications related to each of the interventions, additional interventions, treatment failures and costs (cost-effectiveness and cost-utility) after 1 year. CONCLUSION AND IMPLICATIONS: Based on the results of this proposed large study well-founded adjustments of existing guidelines on the treatment of iliac artery occlusive disease can be implemented (Clinical Trials.gov NCT01385774; Nederlands Trial Register NTR2776). Copyright Â
Authors: Farzin Fakhry; Hugo Jp Fokkenrood; Sandra Spronk; Joep Aw Teijink; Ellen V Rouwet; M G Myriam Hunink Journal: Cochrane Database Syst Rev Date: 2018-03-08
Authors: Anne P Conijn; Wilma Jonkers; Ellen V Rouwet; Anco C Vahl; Jim A Reekers; Mark J W Koelemay Journal: Cardiovasc Intervent Radiol Date: 2015-03-14 Impact factor: 2.740
Authors: Anne Sofie F Larsen; Anne Therese Reiersen; Morten B Jacobsen; Nils-Einar Kløw; Joakim Nordanstig; Mark Morgan; Jarlis Wesche Journal: Health Qual Life Outcomes Date: 2017-09-22 Impact factor: 3.186
Authors: Marijn Ml van den Houten; Sandra Cp Jansen; Anneroos Sinnige; Lijckle van der Laan; Patrick Whe Vriens; Edith M Willigendael; Jan-Willem Hp Lardenoije; Jan-Willem M Elshof; Eline S van Hattum; Maarten A Lijkwan; Ivan Nyklíček; Ellen V Rouwet; Mark Jw Koelemay; Marc Rm Scheltinga; Joep Aw Teijink Journal: BMJ Open Date: 2019-02-19 Impact factor: 2.692